Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

• Status: Recruiting
• Trial end date: 2023-03-13
• Target enrollment: 0
• Participant gender: All

Summary

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S

Criteria

Inclusion Criteria:

• Participants diagnosed (clinically) with type 2 diabetes greater than equal to (≥) 90 days prior to the screening visit.

• Stable daily dose of Oral Antidiabetic Drug (OAD) and/or insulin treatment for ≥ 60 days prior to the screening visit.

• HbA1c 7.5-10% (59-86 millimoles per mole [mmol/mol]) (both inclusive) in Visit 1.

• Participants in which Ozempic is indicated according to approved local label.

• Fundoscopy/Fundus photography record less than equal to (≤) 12 months.

Exclusion Criteria:

• Known or suspected hypersensitivity to study intervention(s) or related products.

• Previous participation in this study. Participation is defined as signed informed consent.

• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.

• Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before the screening visit, except Coronavirus Disease 2019 (COVID-19) related trials (this is allowed).

• Treatment with any glucagon-like peptide-1 receptor agonists (GLP-1 RA) medication prior to the screening visit.

• Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

• Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma.

• History of pancreatitis (acute or chronic).

• Renal impairment defined as estimated glomerular filtration rate (eGFR) below 30 milliliters/minute (mL/min)/1.73 meter square (m^2) as per MDRD-4 (Modification of Diet in Renal Disease).

• Myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening.

• Participants presently classified as being in New York Heart Association (NYHA) Class IV heart failure.

• Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.

• Participants with alanine aminotransferase (ALT) > 2.5 x upper normal limit (UNL).

• Use of systemic immunosuppressive treatment within 90 days prior to screening.

• Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of ≤ 14 days.

• Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episodes as judged by the investigator.

• Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 12 months prior to screening.

• History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).